MX366419B - Celulas madre mesenquimales primarias inmunoprotectoras y metodos. - Google Patents

Celulas madre mesenquimales primarias inmunoprotectoras y metodos.

Info

Publication number
MX366419B
MX366419B MX2015013387A MX2015013387A MX366419B MX 366419 B MX366419 B MX 366419B MX 2015013387 A MX2015013387 A MX 2015013387A MX 2015013387 A MX2015013387 A MX 2015013387A MX 366419 B MX366419 B MX 366419B
Authority
MX
Mexico
Prior art keywords
methods
stem cells
mesenchymal stem
primary mesenchymal
polypeptides
Prior art date
Application number
MX2015013387A
Other languages
English (en)
Other versions
MX2015013387A (es
Inventor
F Garry Robert
B Wilson Russell
M Branco Luis
A Bunnell Bruce
E Hopkins Samuel
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of MX2015013387A publication Critical patent/MX2015013387A/es
Publication of MX366419B publication Critical patent/MX366419B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invención se refiere a células madre mesenquimales primarias inmunoprotectoras (IP-MSC) que expresan episomalmente polipéptidos inmunoreactivos múltiples que dirigen específicamente un patógeno (por ejemplo, un especie infecciosa de virus, bacteria, o parásito) o toxina. La IPMSC expresa dos o más (por ejemplo, 2 hasta alrededor de 100) polipéptidos inmunoreactivos (por ejemplo, anticuerpos completos, anticuerpos de cadena sencilla (ScFV), fragmentos de anticuerpo Fab o F(ab)2, diacuerpos, tricuerpos, y similares), y opcionalmente uno o más de otros polipéptidos inmunomoduladores, por ejemplo, una citoquina tal como una interleucina (por ejemplo, IL-2, IL-4, IL-6, IL-7, IL-9, e IL-12), un interferón (por ejemplo, IFNa, IFNß, o IFN?), y similares, que pueden aumentar la efectividad de los polipéptidos inmunoreactivos.
MX2015013387A 2013-03-14 2014-03-13 Celulas madre mesenquimales primarias inmunoprotectoras y metodos. MX366419B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/826,285 US9101597B2 (en) 2013-03-14 2013-03-14 Immunoprotective primary mesenchymal stem cells and methods
PCT/US2014/025941 WO2014160157A1 (en) 2013-03-14 2014-03-13 Immunoprotective primary mesenchymal stem cells and methods

Publications (2)

Publication Number Publication Date
MX2015013387A MX2015013387A (es) 2016-08-11
MX366419B true MX366419B (es) 2019-07-08

Family

ID=51527936

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019000704A MX2019000704A (es) 2013-03-14 2014-03-13 Celulas madre mesenquimales primarias inmunoprotectoras y metodos.
MX2015013387A MX366419B (es) 2013-03-14 2014-03-13 Celulas madre mesenquimales primarias inmunoprotectoras y metodos.
MX2019008195A MX2019008195A (es) 2013-03-14 2015-09-14 Celulas madre mesenquimales primarias inmunoprotectoras y metodos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019000704A MX2019000704A (es) 2013-03-14 2014-03-13 Celulas madre mesenquimales primarias inmunoprotectoras y metodos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008195A MX2019008195A (es) 2013-03-14 2015-09-14 Celulas madre mesenquimales primarias inmunoprotectoras y metodos.

Country Status (13)

Country Link
US (4) US9101597B2 (es)
EP (1) EP2968611B1 (es)
JP (1) JP6566932B2 (es)
CN (1) CN105188768B (es)
AR (1) AR095368A1 (es)
AU (1) AU2014244057B2 (es)
CA (1) CA2906592C (es)
EA (1) EA201591673A1 (es)
ES (1) ES2881383T3 (es)
HK (1) HK1219050A1 (es)
MX (3) MX2019000704A (es)
TW (2) TWI650420B (es)
WO (1) WO2014160157A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101597B2 (en) * 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
US11357866B2 (en) * 2013-04-03 2022-06-14 The Administrators Of The Tulane Educational Fund Expression of HIV inhibitors by mesenchymal stem cells
US20170239297A1 (en) 2014-08-18 2017-08-24 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
US10654943B2 (en) 2015-06-02 2020-05-19 The Rockefeller University Tri-specific antibodies for HIV therapy
KR20180105705A (ko) 2016-02-04 2018-09-28 롱에버론 엘엘씨 백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법
US10201592B2 (en) 2016-06-07 2019-02-12 The Pacific Heart, Lung, & Blood Institute Compositions and methods for treating mesothelioma post-surgery
CN110913891A (zh) * 2016-12-05 2020-03-24 图兰恩教育基金管理人 沙粒病毒单克隆抗体和用途
CA3150235A1 (en) * 2019-09-05 2021-03-11 Alireza Rezania UNIVERSAL DONOR CELLS
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
US20230105667A1 (en) * 2020-03-12 2023-04-06 Exostem Biotec Ltd. Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis
EP3881853A1 (en) * 2020-03-20 2021-09-22 Promethera Therapeutics Sa Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation
US20210299246A1 (en) * 2020-03-27 2021-09-30 R. Brannon Claytor Methods and compositions for therapeutic treatment of viral or virally-induced infections and conditions, and anti-viral compositions and their production
US11566230B2 (en) 2020-12-31 2023-01-31 Crispr Therapeutics Ag Universal donor cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039186A1 (en) * 1997-02-28 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
US6149906A (en) * 1997-09-20 2000-11-21 Osiris Therapeutics, Inc. Antigen presenting cells of the adipocyte lineage
EP1373318A2 (en) 2001-01-26 2004-01-02 Abgenix, Inc. Neutralizing human monoclonal antibodies against hiv-1, their production and uses
US20070196365A1 (en) * 2001-02-20 2007-08-23 Dov Zipori Immunoglobulin heavy chain variants expressed in mesenchymal cells and therapeutic uses thereof
US20050053587A1 (en) * 2001-09-20 2005-03-10 Jacques Galipeau Cultured stromal cells and uses thereof
JPWO2005094846A1 (ja) * 2004-03-30 2008-02-14 株式会社レノメディクス研究所 プリオン病治療剤およびその製造方法
CN101166546A (zh) * 2005-01-21 2008-04-23 因特罗根治疗公司 允许靶细胞长期暴露于治疗性和预防性核酸的局部施用
KR101451117B1 (ko) 2005-05-18 2014-10-16 바이오팩투라 인코퍼레이티드 형질감염된 세포의 대사적 선별을 위한 조성물 및 방법
CN1872344A (zh) * 2005-06-01 2006-12-06 上海二医新生基因科技有限公司 人异体间质干细胞（携带治疗基因）的基因治疗方法
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US9005599B2 (en) * 2008-04-21 2015-04-14 Tissue Regeneration Therapeutics Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US9707322B2 (en) * 2012-12-21 2017-07-18 University Of Connecticut Gradient porous scaffolds
US10472647B2 (en) * 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
US9101597B2 (en) * 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods

Also Published As

Publication number Publication date
MX2019008195A (es) 2019-09-11
TWI689590B (zh) 2020-04-01
CA2906592C (en) 2022-01-18
EA201591673A1 (ru) 2016-01-29
US10357562B2 (en) 2019-07-23
MX2015013387A (es) 2016-08-11
CN105188768B (zh) 2019-06-28
EP2968611A4 (en) 2016-08-17
HK1219050A1 (zh) 2017-03-24
EP2968611A1 (en) 2016-01-20
ES2881383T3 (es) 2021-11-29
CN105188768A (zh) 2015-12-23
TW201907005A (zh) 2019-02-16
AU2014244057B2 (en) 2018-12-06
TW201514301A (zh) 2015-04-16
CA2906592A1 (en) 2014-10-02
US11123427B2 (en) 2021-09-21
JP6566932B2 (ja) 2019-08-28
US20160129110A1 (en) 2016-05-12
US9101597B2 (en) 2015-08-11
US20140271580A1 (en) 2014-09-18
EP2968611B1 (en) 2021-05-05
MX2019000704A (es) 2020-11-12
AU2014244057A1 (en) 2015-10-29
US20210401984A1 (en) 2021-12-30
JP2016518819A (ja) 2016-06-30
AR095368A1 (es) 2015-10-14
US20190282694A1 (en) 2019-09-19
WO2014160157A1 (en) 2014-10-02
TWI650420B (zh) 2019-02-11

Similar Documents

Publication Publication Date Title
MX2019008195A (es) Celulas madre mesenquimales primarias inmunoprotectoras y metodos.
NZ736026A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MY184266A (en) Anti-cgrp antibody formulation
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
MX2018016364A (es) Anticuerpos anti-pd-l1.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
MY186352A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
CR20200087A (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
EP3098316A4 (en) Human-derived insect-resistant gene and anti-cry1b toxin idiotype single-chain antibody encoded thereby and application thereof
MX2018006410A (es) Proteinas de union a cd131 y usos de las mismas.
MX2019013370A (es) Constructos de anticuerpos de ácidos nucleicos optimizados.
DK3455261T3 (da) Anti-ror2-antistoffer, antistoffragmenter, immunkonjugater deraf og anvendelser deraf
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
EP3048171A4 (en) Anthropogenic insect-resistant gene and cry1c toxin idiotype single-chain antibody encoded thereby and application thereof
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof
CL2017001471A1 (es) Nueva estructura de proteína producida por un anticuerpo efectivo usado para inmunización

Legal Events

Date Code Title Description
FG Grant or registration